ERBB2 and non-small cell lung carcinoma: T-DXd has FDA approvals for HER2 positive, and HER2 low, unresectable, or metastatic breast cancer after prior chemotherapy, for previously treated HER2 positive gastric cancer, and for previously treated HER2 mutant non-small cell lung cancer.